Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's drug

This page shows the latest Alzheimer's drug news and features for those working in and with pharma, biotech and healthcare.

Lilly’s anti-amyloid antibody donanemab renews Alzheimers hopes

Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes

Drug demonstrated a 'significant' slowing of cognitive decline. Eli Lilly’s amyloid-targeting antibody donanemab has shown promise in the treatment of Alzheimer’s disease, sending its stocks soaring and renewing ... confirmed in 2016 that the company

Latest news

More from news
Approximately 1 fully matching, plus 127 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... Organisations including the Alzheimer’s Drug Discovery Foundation (ADDF) think combinations of molecules with these

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate. ... It was just another in a string of late-stage

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimers disease R&D?

    This evidence has spurred research and led. organisations including the Alzheimer’s Drug Discovery Foundation and AC Immune to conclude that combination therapies may be needed to tackle such a complex ... Read more: Brain power: fresh approaches to

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimers drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc. ... Corporate acquisition. 400.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Bone Therapeutics looks to Pfizer for clinical head Bone Therapeutics looks to Pfizer for clinical head

    He has spent a majority of his career at Pfizer, where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's ... disease drug Aricept and medical team leader for its anti-inflammatory

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics